Media stories about TearLab Corporation (NASDAQ:TEAR) have been trending somewhat negative on Tuesday, Accern reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TearLab Corporation earned a daily sentiment score of -0.06 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 50 out of 100, meaning that recent press coverage is somewhat likely to have an impact on the company’s share price in the immediate future.
A number of brokerages have weighed in on TEAR. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of TearLab Corporation in a research report on Tuesday, May 16th. Zacks Investment Research downgraded TearLab Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. Finally, Rodman & Renshaw lowered their price target on TearLab Corporation from $12.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, May 16th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. TearLab Corporation has an average rating of “Buy” and an average price target of $5.05.
TearLab Corporation (TEAR) traded down 1.81% during trading on Tuesday, hitting $2.17. The stock had a trading volume of 100,781 shares. The firm has a 50 day moving average price of $2.03 and a 200-day moving average price of $3.14. TearLab Corporation has a 1-year low of $1.55 and a 1-year high of $8.30. The firm’s market capitalization is $12.44 million.
TearLab Corporation (NASDAQ:TEAR) last issued its quarterly earnings results on Monday, May 15th. The medical research company reported ($0.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by $0.07. The firm had revenue of $6.70 million for the quarter, compared to the consensus estimate of $7.02 million. During the same period in the prior year, the firm posted ($0.21) EPS. The firm’s revenue was down 1.5% compared to the same quarter last year. On average, equities research analysts expect that TearLab Corporation will post ($2.82) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by BBNS and is owned by of BBNS. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/somewhat-critical-news-coverage-somewhat-likely-to-affect-tearlab-corporation-tear-share-price-updated-updated-updated/1196354.html.
About TearLab Corporation
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.
Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with our FREE daily email newsletter.